Weizmann Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 15, 2025, 9:29 pm

Quick Insight

Weizmann Ltd, operating in the Textiles – Processing/Texturising industry, currently has a share price of 110 with a market capitalization of 177 Cr. The company's low ROE of 5.39% and negative Net Profit of -4 indicate potential profitability concerns. However, the healthy ROCE of 15.8% reflects efficient capital utilization. With a P/BV of 2.73x and an ICR of 29.31x, the company's valuation and ability to meet short-term obligations seem reasonable. The high promoter holding of 68.34% signals confidence from insiders. Overall, investors should closely monitor Weizmann Ltd's profitability trends and management's strategies to drive sustainable growth in the competitive textile sector.

Competitors of Weizmann Ltd

All Competitor Stocks of Weizmann Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:18 am

Below is a detailed analysis of the quarterly data for Weizmann Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 36.25 Cr.. The value appears strong and on an upward trend. It has increased from 28.58 Cr. (Dec 2024) to 36.25 Cr., marking an increase of 7.67 Cr..
• For Expenses, as of Mar 2025, the value is 31.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.39 Cr. (Dec 2024) to 31.20 Cr., marking an increase of 6.81 Cr..
• For Operating Profit, as of Mar 2025, the value is 5.05 Cr.. The value appears strong and on an upward trend. It has increased from 4.19 Cr. (Dec 2024) to 5.05 Cr., marking an increase of 0.86 Cr..
• For OPM %, as of Mar 2025, the value is 13.93%. The value appears to be declining and may need further review. It has decreased from 14.66% (Dec 2024) to 13.93%, marking a decrease of 0.73%.
• For Other Income, as of Mar 2025, the value is 0.06 Cr.. The value appears to be declining and may need further review. It has decreased from 0.09 Cr. (Dec 2024) to 0.06 Cr., marking a decrease of 0.03 Cr..
• For Interest, as of Mar 2025, the value is 0.23 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.39 Cr. (Dec 2024) to 0.23 Cr., marking a decrease of 0.16 Cr..
• For Depreciation, as of Mar 2025, the value is 1.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.71 Cr. (Dec 2024) to 1.37 Cr., marking an increase of 0.66 Cr..
• For Profit before tax, as of Mar 2025, the value is 3.51 Cr.. The value appears strong and on an upward trend. It has increased from 3.18 Cr. (Dec 2024) to 3.51 Cr., marking an increase of 0.33 Cr..
• For Tax %, as of Mar 2025, the value is 33.90%. The value appears to be increasing, which may not be favorable. It has increased from 25.79% (Dec 2024) to 33.90%, marking an increase of 8.11%.
• For Net Profit, as of Mar 2025, the value is -8.68 Cr.. The value appears to be declining and may need further review. It has decreased from 1.99 Cr. (Dec 2024) to -8.68 Cr., marking a decrease of 10.67 Cr..
• For EPS in Rs, as of Mar 2025, the value is -5.47. The value appears to be declining and may need further review. It has decreased from 1.25 (Dec 2024) to -5.47, marking a decrease of 6.72.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:25 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:04 pm

Below is a detailed analysis of the balance sheet data for Weizmann Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 16.00 Cr. (Mar 2024) to 15.00 Cr., marking a decrease of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 45.00 Cr.. The value appears to be declining and may need further review. It has decreased from 57.00 Cr. (Mar 2024) to 45.00 Cr., marking a decrease of 12.00 Cr..
• For Borrowings, as of Mar 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 8.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 3.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Mar 2024) to 19.00 Cr., marking an increase of 2.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 91.00 Cr.. The value appears to be improving (decreasing). It has decreased from 97.00 Cr. (Mar 2024) to 91.00 Cr., marking a decrease of 6.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Mar 2024) to 33.00 Cr., marking an increase of 7.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 35.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 13.00 Cr..
• For Other Assets, as of Mar 2025, the value is 35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 35.00 Cr..
• For Total Assets, as of Mar 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2024) to 91.00 Cr., marking a decrease of 6.00 Cr..

Notably, the Reserves (45.00 Cr.) exceed the Borrowings (11.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Weizmann Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -2.32. This value is below the healthy minimum of 5. It has decreased from 5.65 (Mar 24) to -2.32, marking a decrease of 7.97.
• For Diluted EPS (Rs.), as of Mar 25, the value is -2.30. This value is below the healthy minimum of 5. It has decreased from 5.65 (Mar 24) to -2.30, marking a decrease of 7.95.
• For Cash EPS (Rs.), as of Mar 25, the value is 13.15. This value is within the healthy range. It has increased from 7.76 (Mar 24) to 13.15, marking an increase of 5.39.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.28. It has decreased from 45.90 (Mar 24) to 39.28, marking a decrease of 6.62.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.28. It has decreased from 45.90 (Mar 24) to 39.28, marking a decrease of 6.62.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 75.67. It has decreased from 77.50 (Mar 24) to 75.67, marking a decrease of 1.83.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 15.76. This value is within the healthy range. It has increased from 9.66 (Mar 24) to 15.76, marking an increase of 6.10.
• For PBIT / Share (Rs.), as of Mar 25, the value is 13.58. This value is within the healthy range. It has increased from 7.94 (Mar 24) to 13.58, marking an increase of 5.64.
• For PBT / Share (Rs.), as of Mar 25, the value is 13.05. This value is within the healthy range. It has increased from 7.53 (Mar 24) to 13.05, marking an increase of 5.52.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 10.98. This value is within the healthy range. It has increased from 6.04 (Mar 24) to 10.98, marking an increase of 4.94.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.49. This value is within the healthy range. It has decreased from 5.65 (Mar 24) to 3.49, marking a decrease of 2.16.
• For PBDIT Margin (%), as of Mar 25, the value is 20.82. This value is within the healthy range. It has increased from 12.46 (Mar 24) to 20.82, marking an increase of 8.36.
• For PBIT Margin (%), as of Mar 25, the value is 17.95. This value is within the healthy range. It has increased from 10.24 (Mar 24) to 17.95, marking an increase of 7.71.
• For PBT Margin (%), as of Mar 25, the value is 17.24. This value is within the healthy range. It has increased from 9.71 (Mar 24) to 17.24, marking an increase of 7.53.
• For Net Profit Margin (%), as of Mar 25, the value is 14.50. This value exceeds the healthy maximum of 10. It has increased from 7.79 (Mar 24) to 14.50, marking an increase of 6.71.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 8. It has decreased from 7.29 (Mar 24) to 4.60, marking a decrease of 2.69.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.87. This value is below the healthy minimum of 15. It has decreased from 12.30 (Mar 24) to 8.87, marking a decrease of 3.43.
• For Return on Capital Employeed (%), as of Mar 25, the value is 33.05. This value is within the healthy range. It has increased from 16.83 (Mar 24) to 33.05, marking an increase of 16.22.
• For Return On Assets (%), as of Mar 25, the value is 5.95. This value is within the healthy range. It has decreased from 9.21 (Mar 24) to 5.95, marking a decrease of 3.26.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.15. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.15, marking an increase of 0.05.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.25. It has increased from 1.24 (Mar 24) to 1.25, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.96, marking a decrease of 0.06.
• For Quick Ratio (X), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 1. It has increased from 0.58 (Mar 24) to 0.64, marking an increase of 0.06.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.60. This value is below the healthy minimum of 4. It has decreased from 4.55 (Mar 24) to 3.60, marking a decrease of 0.95.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 8.84 (Mar 24) to 0.00, marking a decrease of 8.84.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 6.78 (Mar 24) to 0.00, marking a decrease of 6.78.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 91.16 (Mar 24) to 0.00, marking a decrease of 91.16.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 93.22 (Mar 24) to 0.00, marking a decrease of 93.22.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 29.31. This value is within the healthy range. It has increased from 23.49 (Mar 24) to 29.31, marking an increase of 5.82.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 21.42. This value is within the healthy range. It has increased from 15.68 (Mar 24) to 21.42, marking an increase of 5.74.
• For Enterprise Value (Cr.), as of Mar 25, the value is 174.57. It has decreased from 182.48 (Mar 24) to 174.57, marking a decrease of 7.91.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.49. This value is within the healthy range. It has increased from 1.48 (Mar 24) to 1.49, marking an increase of 0.01.
• For EV / EBITDA (X), as of Mar 25, the value is 7.15. This value is within the healthy range. It has decreased from 11.91 (Mar 24) to 7.15, marking a decrease of 4.76.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has decreased from 1.43 (Mar 24) to 1.41, marking a decrease of 0.02.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 91.15 (Mar 24) to 0.00, marking a decrease of 91.15.
• For Price / BV (X), as of Mar 25, the value is 2.73. This value is within the healthy range. It has increased from 2.42 (Mar 24) to 2.73, marking an increase of 0.31.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has decreased from 1.43 (Mar 24) to 1.41, marking a decrease of 0.02.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.03, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness